Edaglitazone is a potent, selective and orally activePPARγagonist, withEC₅₀s of 35.6 nM and 1053 nM forPPARαandPPARγ, respectively. Edaglitazone displays antiplatelet, antidiabetic and anti-hyperglycemic activity^[1][2][3].

Edaglitazone (3-16 μM; 5 min) inhibits the collagen (1.2 μg/mL)-induced platelet aggregation. Edaglitazone increases the intraplatelet levels of cAMP in a concentration dependent manner. Edaglitazone preventes the Collagen-induced intraplatelet levels of PPARγ decrease^[3].

Edaglitazone (4.4 mg/kg; p.o. daily for 10 days) enhances insulin sensitivity in obese rats^[2].

464.56

C₂₄H₂₀N₂O₄S₂

213411-83-7

依格列宗

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.